Autologous CD19 CAR T therapy has been introduced into the field of hemato-oncology with the demonstration of ground-breaking results for patients with R/R B Cell lymphoma (39) and B cell - acute lymphoblastic leukemia (ALL) (40), with response rates of 64% and 81% in the initial reports, respectively. Here, CD19 is linked to acute lymphoblastic leukemia.